Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2018 Oct 18;8(1):15376.
doi: 10.1038/s41598-018-33735-x.

Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation

Affiliations
Controlled Clinical Trial

Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation

Sheila Z Kimaro Mlacha et al. Sci Rep. .

Abstract

Children in developing countries are frequently exposed to the pneumococcus, but few develop invasive pneumococcal disease (IPD). We test the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that these differences are sufficiently great to affect susceptibility to and outcome of IPD. We recruited children aged 24-36 months, who had recovered from IPD, and age-matched healthy controls and vaccinated them with 1 dose of the 23-valent PPV to mimic natural exposure. We collected serum samples after vaccination and analysed the dynamics of anti-polysaccharide antibody responses to several capsular antigens. Mean IgG response times to different serotypes were 6.4-7.3 days, with standard deviations of 0.9-1.85 days, suggesting a natural range in response times of up to 7 days. Serotype 1 elicited the largest fold-rise, serotype 23F the smallest. The proportion of responses achieved by day 7 was similar in children with a history of IPD and healthy children. There was considerable natural variation in the rapidity of anti-capsular IgG responses extending over 4-7 days. There was no evidence to suggest that children who have experienced IPD respond more slowly to heterologous pneumococcal capsular antigens than do healthy children.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Geometric mean concentrations of antibodies to pneumococcal serotypes 1, 6B, 14, 19F and 23F, before and after immunization with polysaccharide vaccine in healthy children (n = 36).
Figure 2
Figure 2
Cumulative distribution curves representing the proportion of children reaching the response threshold (half of the maximum) against time since vaccination for serotype 1, 6B, 14, 19F and 23F.
Figure 3
Figure 3
Proportion of the total antibody concentration rise achieved by 7 days for five capsular antibodies among Prior IPD and Healthy Control groups. Box plots show 25th and 75th percentiles, error bars show 10th and 90th percentailes and median values are shown as (−). Proportional rise = C7 − C0/C11 − C0 where C0, C7 and C11 represent concentrations on day 0, 7 and 11 respectively. IPD = Invasive Pneumococcal Disease *P < 0.05 (Wilcoxon rank sum test).

Similar articles

References

    1. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171:1387–1398. doi: 10.1093/infdis/171.6.1387. - DOI - PubMed
    1. Pourpak Z, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:114–120. - PubMed
    1. Aghamohammadi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40:113–118. doi: 10.1016/S0928-8244(03)00304-3. - DOI - PubMed
    1. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30. doi: 10.1016/j.clim.2010.06.012. - DOI - PubMed
    1. Bangert M, et al. P4-mediated antibody therapy in an acute model of invasive pneumococcal disease. The Journal of infectious diseases. 2012;205:1399–1407. doi: 10.1093/infdis/jis223. - DOI - PubMed

Publication types